CS logo
small CS logo
Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica

Milano, Lombardia, Italy
Research institute in Milan
Via Giacomo Venezian, 1, 20133 Milano MI

About Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica


  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
6
Genentech, Inc.
1
Total Rows: 2

Clinical Trials at Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica


During the past decade, Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 4 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.
Created with Highcharts 11.1.0TrialsTrials Trend - Last 10 Years11001100221111000000Started TrialsCompleted Trails201520162017201820190123
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
2009-10-29
2014-07-09
Completed
361
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
2012-10-22
2016-04-28
Completed
208
A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors
2014-08-19
2019-08-31
Completed
124
Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer
2015-07-28
2019-01-15
Completed
152
A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
2017-03-08
2022-08-12
Completed
1,301
A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer
2019-01-09
2023-07-01
Active, not recruiting
70
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
2019-02-28
2028-07-05
Recruiting
1,000

Rows per page:

1–7 of 7

Clinical Trials Sponsors and Collaborators


In terms of collaborators to trials, out of the total clinical trials conducted in "Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica" #1 collaborator was "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator and "GOG Foundation" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.
Created with Highcharts 11.1.0Top Leading Sponsors

Created with Highcharts 11.1.0Top Collaborators

Clinical Trials Conditions at Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica


According to Clinical.Site data, the most researched conditions in "Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica" are "Ovarian Cancer" (3 trials), "Breast Neoplasms" (1 trials), "Cancer" (1 trials), "Cervical Cancer" (1 trials) and "Fallopian Tube Cancer" (1 trials). Many other conditions were trialed in "Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica" in a lesser frequency.

Clinical Trials Intervention Types at Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica


Most popular intervention types in "Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica" are "Drug" (7 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (3 trials), "Bevacizumab" (3 trials), "Paclitaxel" (3 trials), "Carboplatin" (2 trials) and "Placebo" (2 trials). Other intervention names were less common.

Clinical Trials Genders at Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica


The vast majority of trials in "Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica" are 6 trials for "Female" genders and 1 trials for "All" genders.

Clinical Trials Status at Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica


Currently, there are NaN active trials in "Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica, undefined suspended trials, and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica, 1 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".
Created with Highcharts 11.1.0Trials By Phase

Created with Highcharts 11.1.0Trials Status